Tarveda Therapeutics

company

About

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$21M
Industries
Biotechnology,Health Care,Health Diagnostics,Medical,Therapeutics
Founded date
Jan 1, 2012
Number Of Employee
11 - 50
Operating Status
Active

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$51M
Tarveda Therapeutics has raised a total of $51M in funding over 2 rounds. Their latest funding was raised on Feb 2, 2017 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 2, 2017 Series D $30M 1 Versant Ventures Detail
Jan 7, 2015 Series B $21M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Tarveda Therapeutics is funded by 2 investors. Versant Ventures and Eminent Venture Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures Yes Series D
Eminent Venture Capital Series B